Keisuke Asakura1,2, Yukihiro Yoshida3, Hiroyuki Sakurai3,4, Kazuo Nakagawa3, Noriko Motoi5, Shun-Ichi Watanabe3. 1. Department of Thoracic Surgery, National Cancer Center Hospital, 5-1-1, Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan. asakurakeisuke@gmail.com. 2. Division of Thoracic Surgery, Keio University School of Medicine, Tokyo, Japan. asakurakeisuke@gmail.com. 3. Department of Thoracic Surgery, National Cancer Center Hospital, 5-1-1, Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan. 4. Division of Respiratory Surgery, Nihon University School of Medicine, Tokyo, Japan. 5. Department of Pathology and Clinical Laboratories, National Cancer Center Hospital, Tokyo, Japan.
Abstract
BACKGROUND: Good prognosis following surgery for metachronous lung cancer has been reported. However, prognostic factors have not been fully investigated. The purpose of this study was to identify the preoperative predictor of survival in metachronous lung cancer. METHODS: Patients who underwent a second pulmonary resection for metachronous lung cancer at our institution between 2000 and 2014 were analyzed. RESULTS: A retrospective chart review identified 86 eligible patients (of 6213; 1.4%). The 5-year overall survival was 77%. All 86 cancers met Martini and Melamed's criteria for second primary cancer. However, on pathological examination based on morphological concordance between the initial and metachronous cancer, 73 (85%) cases were diagnosed as second primary cancer and 13 (15%) as a possible recurrent tumor. The 5-year overall survivals were 82% for second primary cancers and 52% for possible recurrent tumors. Tumor doubling time > 180 days (p < 0.001), pathological diagnosis of second primary cancer (p = 0.013), pathological stage IA (p = 0.016), interval between resections > 2 years (p = 0.040), and consolidation/tumor diameter ratio ≤ 0.5 (p = 0.045) were associated with superior overall survival. Multivariate Cox regression analysis identified tumor doubling time > 180 days as the only independent predictor of overall survival (hazard ratio 3.600, 95% confidence interval 1.226-10.338; p = 0.0196). CONCLUSIONS: Surgical resection for metachronous lung cancer is effective and feasible. Particularly, a tumor doubling time > 180 days is associated with superior survival in patients with metachronous lung cancer.
BACKGROUND: Good prognosis following surgery for metachronous lung cancer has been reported. However, prognostic factors have not been fully investigated. The purpose of this study was to identify the preoperative predictor of survival in metachronous lung cancer. METHODS:Patients who underwent a second pulmonary resection for metachronous lung cancer at our institution between 2000 and 2014 were analyzed. RESULTS: A retrospective chart review identified 86 eligible patients (of 6213; 1.4%). The 5-year overall survival was 77%. All 86 cancers met Martini and Melamed's criteria for second primary cancer. However, on pathological examination based on morphological concordance between the initial and metachronous cancer, 73 (85%) cases were diagnosed as second primary cancer and 13 (15%) as a possible recurrent tumor. The 5-year overall survivals were 82% for second primary cancers and 52% for possible recurrent tumors. Tumor doubling time > 180 days (p < 0.001), pathological diagnosis of second primary cancer (p = 0.013), pathological stage IA (p = 0.016), interval between resections > 2 years (p = 0.040), and consolidation/tumor diameter ratio ≤ 0.5 (p = 0.045) were associated with superior overall survival. Multivariate Cox regression analysis identified tumor doubling time > 180 days as the only independent predictor of overall survival (hazard ratio 3.600, 95% confidence interval 1.226-10.338; p = 0.0196). CONCLUSIONS: Surgical resection for metachronous lung cancer is effective and feasible. Particularly, a tumor doubling time > 180 days is associated with superior survival in patients with metachronous lung cancer.
Authors: Andrew G Nicholson; Kathleen Torkko; Patrizia Viola; Edwina Duhig; Kim Geisinger; Alain C Borczuk; Kenzo Hiroshima; Ming S Tsao; Arne Warth; Sylvie Lantuejoul; Prudence A Russell; Erik Thunnissen; Alberto Marchevsky; Mari Mino-Kenudson; Mary Beth Beasley; Johan Botling; Sanja Dacic; Yasushi Yatabe; Masayuki Noguchi; William D Travis; Keith Kerr; Fred R Hirsch; Lucian R Chirieac; Ignacio I Wistuba; Andre Moreira; Jin-Haeng Chung; Teh Ying Chou; Lukas Bubendorf; Gang Chen; Giuseppe Pelosi; Claudia Poleri; Frank C Detterbeck; Wilbur A Franklin Journal: J Thorac Oncol Date: 2017-11-07 Impact factor: 15.609
Authors: Mi Kyung Bae; Chun Sung Byun; Chang Young Lee; Jin Gu Lee; In Kyu Park; Dae Joon Kim; Kyung Young Chung Journal: Ann Thorac Surg Date: 2011-05-19 Impact factor: 4.330
Authors: Nicolas Girard; Charuhas Deshpande; Christopher Lau; David Finley; Valerie Rusch; William Pao; William D Travis Journal: Am J Surg Pathol Date: 2009-12 Impact factor: 6.394
Authors: Benjamin E Lee; Jeff L Port; Brendon M Stiles; James Saunders; Subroto Paul; Paul C Lee; Nasser Altorki Journal: Ann Thorac Surg Date: 2009-10 Impact factor: 4.330
Authors: Richard J Battafarano; Seth D Force; Bryan F Meyers; Jennifer Bell; Tracey J Guthrie; Joel D Cooper; G Alexander Patterson Journal: J Thorac Cardiovasc Surg Date: 2004-03 Impact factor: 5.209
Authors: K Usuda; Y Saito; M Sagawa; M Sato; K Kanma; S Takahashi; C Endo; Y Chen; A Sakurada; S Fujimura Journal: Cancer Date: 1994-10-15 Impact factor: 6.860
Authors: Feiran Lou; James Huang; Camelia S Sima; Joseph Dycoco; Valerie Rusch; Peter B Bach Journal: J Thorac Cardiovasc Surg Date: 2012-11-03 Impact factor: 5.209
Authors: Stéphane Vignot; Garrett M Frampton; Jean-Charles Soria; Roman Yelensky; Frédéric Commo; Christian Brambilla; Gary Palmer; Denis Moro-Sibilot; Jeffrey S Ross; Maureen T Cronin; Fabrice André; Philip J Stephens; Vladimir Lazar; Vincent A Miller; Elisabeth Brambilla Journal: J Clin Oncol Date: 2013-04-29 Impact factor: 44.544